Portal vein thrombosis: A concise review (…
https://www.spandidos-publications.com/10.3892/etm.2021.10191
LMWH (low molecular weight heparine) is the most utilized in patients with cirrhosis, non‑malignancies, infections, or those who are awaiting a liver transplant. DOACs (direct‑acting oral anticoagulants) may be used in the rest of the medical conditions, being safe and equal to LMWH. Anticoagulation for patients with cirrhosis who experience portal vein thrombosis is usually not advised unless they have chronic PVT 1) with thrombophilia, 2) with clot burden in the mesenteric veins, or 3) inadequate blood supply to the bowels. Treatment options include anticoagulants and interventional thrombolytic therapies, which are chosen almost on a case-by-case basis depending on the characteristics of the patient and the thrombus.
LMWH (low molecular weight heparine) is the most utilized in patients with cirrhosis, non‑malignancies, infections, or those who are awaiting a liver transplant.
DOACs (direct‑acting oral anticoagulants) may be used in the rest of the medical conditions, being safe and equal to LMWH.
Anticoagulation for patients with cirrhosis who experience portal vein thrombosis is usually not advised unless they have chronic PVT 1) with thrombophilia, 2) with clot burden in the mesenteric veins, or 3) inadequate blood supply to the bowels.
Treatment options include anticoagulants and interventional thrombolytic therapies, which are chosen almost on a case-by-case basis depending on the characteristics of the patient and the thrombus.
DA: 78 PA: 62 MOZ Rank: 46
